Intellia Therapeutics (NTLA) Enterprise Value (2015 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Enterprise Value of -$376.0 million for Q1 2026, up 25.36% year-over-year from -$299.9 million in Q1 2025, and up 16.43% quarter-over-quarter from -$449.9 million in Q4 2025.
Intellia Therapeutics (NTLA) Enterprise Value (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Enterprise Value for 12 consecutive years, with -$376.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value rose 25.36% year-over-year to -$376.0 million; the TTM figure through Mar 2026 stood at -$376.0 million (up 25.36% YoY), while the FY2025 annual figure was -$449.9 million, up 25.21% from the prior year.
- Enterprise Value advanced to -$376.0 million in Q1 2026 per NTLA's latest filing, from -$449.9 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$376.0 million in Q1 2026 and bottomed at -$933.5 million in Q1 2023.
- Historically, Enterprise Value has averaged -$690.0 million across 5 years, with a median of -$691.1 million in 2024.
- Annual changes were most pronounced in 2022 — Enterprise Value slumped 65.26% — and 2025, when it jumped 36.34%.
- Intellia Therapeutics' Enterprise Value stood at -$681.1 million in 2022, then tumbled by 33.94% to -$912.2 million in 2023, then soared by 34.06% to -$601.5 million in 2024, then grew by 25.21% to -$449.9 million in 2025, then increased by 16.43% to -$376.0 million in 2026.
- Business Quant data shows NTLA's Enterprise Value at -$376.0 million in Q1 2026, -$449.9 million in Q4 2025, and -$511.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - | -437.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -437.76 Mn |
| Mar 31, 2026 | -375.99 Mn |
| Dec 31, 2025 | -449.88 Mn |
| Sep 30, 2025 | -511.04 Mn |
| Jun 30, 2025 | -459.65 Mn |
| Mar 31, 2025 | -503.75 Mn |
| Dec 31, 2024 | -601.52 Mn |
| Sep 30, 2024 | -658.11 Mn |
| Jun 30, 2024 | -691.07 Mn |
| Mar 31, 2024 | -791.29 Mn |
| Dec 31, 2023 | -912.22 Mn |
| Sep 30, 2023 | -854.79 Mn |
| Jun 30, 2023 | -748.23 Mn |
| Mar 31, 2023 | -933.54 Mn |
| Dec 31, 2022 | -681.07 Mn |
| Sep 30, 2022 | -828.19 Mn |
| Jun 30, 2022 | -874.28 Mn |
| Mar 31, 2022 | -855.25 Mn |
| Dec 31, 2021 | -750.77 Mn |
| Sep 30, 2021 | -798.27 Mn |